Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Bioheng Therapeutics logo — We are committed to exploring the frontier of cell therapy,...

Bioheng Therapeutics

We are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T

Founded 2017 United States United States 12 employees

General Information

Company Name Bioheng Therapeutics
Founded Year 2017
Location United States United States +1
Employees 12
Social

Get notified when Bioheng Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Bioheng Therapeutics

Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T. Founded in 2017, we aim to develop the world's leading allogeneic cell therapy products to address some of the most challenging the unmet needs. In March 2020, Bioheng received IND approval for CTA101, marking the first UCAR-T IND in China. In January 2023, our CD7-targeted UCAR-T, CTD401, received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of T-ALL. This groundbreaking product is based on Bioheng's next-generation, novel, and proprietary UCAR-T technology platform—ANSWER CAR. As Bioheng's flagship asset, the CD7 UCAR-T has been dosed in nearly a hundred patients in an Investigator-Initiated Trial (IIT) clinical study, demonstrating excellent efficacy and safety. We are advancing the global clinical trial for this pipeline.

No funding data available for Bioheng Therapeutics yet.

Get notified when Bioheng Therapeutics raises funding

Bioheng Therapeutics Alternatives & Competitors

Bioheng Therapeutics vs
Wugen
Wugen United States

Engineering the Next Generation of Off-the-Shelf Cell Therapies

Series C
51 employees
Biotechnology, Health and Wellness
Bioheng Therapeutics vs
MEDIPOST, Inc.
MEDIPOST, Inc. United States

MEDIPOST, Inc. is a leading commercial-stage biotechnology company specializing in the development o...

21 employees
Bioheng Therapeutics vs
Tessa Therapeutics Ltd
Tessa Therapeutics Ltd Singapore

A clinical-stage biotech company developing autologous and allogeneic cell therapies for the treatme...

Grant
47 employees
Biotechnology, Health Care

FAQ About Bioheng Therapeutics

We are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T
Bioheng Therapeutics was founded in 2017.
Bioheng Therapeutics is headquartered in United States.
Bioheng Therapeutics has approximately 12 employees.
Top alternatives and competitors to Bioheng Therapeutics include Wugen, MEDIPOST, Inc., Tessa Therapeutics Ltd, MacuCLEAR, Luminary Therapeutics, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bioheng Therapeutics and Wugen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Bioheng Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes